Oppenheimer downgraded 89bio to Perform from Outperform with no price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ETNB:
- 89bio price target lowered to $27 from $34 at RBC Capital
- 89bio down 27% after Akero reports NASH trial data
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- 3 Best Stocks to Buy Now, 9/22/2023, According to Top Analysts